PARP1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Anti-tumor agents targeting synthetic lethality, like PARP inhibitors, which have been used in the treatment of DNA repair defective tumors, also have potential in tRCC therapy.